EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

Astragaloside IV Mitigates Hepatocyte Apoptosis in Metabolic Dysfunction–Associated Fatty Liver Disease Through Inhibition of CASP3 ‐Dependent PARP1 Cleavage

Fengyi Zhang iD, Xinhe Wang iD, Yahui Li, Wenlu Ma, Yaxin Chen, Yufeng Zhang, Jiayi Zhang, Xin Wang, Jingjing Pan, Yu Zhang, Ziyang Cheng, Wenbo Wang iD and 1 more

Phytotherapy Research · 2026-11-13

DOI: 10.1002/ptr.70473 ↗

At a glance

Journal article in Phytotherapy Research, published online on 2026-11-13. Written by Fengyi Zhang and 12 co-authors. Institution: Shandong University of Traditional Chinese Medicine, Jinan, China. 32 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Natural Science Foundation of Shandong Province, Special funding for Mount Tai Scholar Project, Shandong University of Traditional Chinese Medicine Quality Improvement and Innovation Project.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Metabolic dysfunction–associated fatty liver disease (MAFLD) is associated with hepatic lipid accumulation, inflammation, and hepatocyte apoptosis. Astragaloside IV (AS‐IV) has been reported to regulate lipid metabolism, but its effects on hepatocyte apoptosis in MAFLD remain unclear. We investigated the effects of AS‐IV in db/db mice and free fatty acid (FFA)–treated HepG2 cells using biochemical assays, histological staining, measurements of inflammatory markers and reactive oxygen species, and apoptosis assays. Network pharmacology and molecular docking were used to identify candidate targets, followed by analyses of CASP3 and PARP1 expression and cleavage and CASP3 overexpression experiments. AS‐IV reduced hepatic and cellular triglyceride accumulation, inflammatory markers, and hepatocyte apoptosis, and improved liver histology and serum markers of liver injury in db/db mice. These effects were accompanied by reduced CASP3 activation and PARP1 cleavage. In HepG2 cells, AS‐IV also attenuated the changes associated with CASP3 overexpression. Together, these findings suggest that suppression of CASP3‐associated PARP1 cleavage may contribute to the protective effects of AS‐IV in these experimental models of MAFLD.

Subjects

Author keywords

Astragaloside IVapoptosiscaspase 3metabolic dysfunction–associated fatty liver diseasepoly‐ADP ribose polymerase‐1

Authors and institutions

  • Shandong University of Traditional Chinese Medicine, Jinan, China.
  • The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.

ORCID profiles: Fengyi Zhang, Xinhe Wang, Wenbo Wang, Yujie Li

Funding

  • Natural Science Foundation of Shandong Province
  • Special funding for Mount Tai Scholar Project
  • Shandong University of Traditional Chinese Medicine Quality Improvement and Innovation Project

Cite

APA

Zhang, F., Wang, X., Li, Y., Ma, W., Chen, Y., Zhang, Y., Zhang, J., Wang, X., Pan, J., Zhang, Y., Cheng, Z., Wang, W., & Li, Y. (2026). Astragaloside IV Mitigates Hepatocyte Apoptosis in Metabolic Dysfunction–Associated Fatty Liver Disease Through Inhibition of CASP3 ‐Dependent PARP1 Cleavage. Phytotherapy Research. https://doi.org/10.1002/ptr.70473

Vancouver

Zhang F, Wang X, Li Y, Ma W, Chen Y, Zhang Y, et al. Astragaloside IV Mitigates Hepatocyte Apoptosis in Metabolic Dysfunction–Associated Fatty Liver Disease Through Inhibition of CASP3 ‐Dependent PARP1 Cleavage. Phytotherapy Research. 2026. doi:10.1002/ptr.70473

BibTeX
@article{Zhang2026,
  author = {Zhang, Fengyi and Wang, Xinhe and Li, Yahui and Ma, Wenlu and Chen, Yaxin and Zhang, Yufeng and Zhang, Jiayi and Wang, Xin and Pan, Jingjing and Zhang, Yu and Cheng, Ziyang and Wang, Wenbo and Li, Yujie},
  title = {Astragaloside IV Mitigates Hepatocyte Apoptosis in Metabolic Dysfunction–Associated Fatty Liver Disease Through Inhibition of CASP3 ‐Dependent PARP1 Cleavage},
  journal = {Phytotherapy Research},
  year = {2026},
  doi = {10.1002/ptr.70473}
}
Start for free →